mRNA Modification Service
The clinical utility of messenger RNA (mRNA) is fundamentally constrained by its inherent instability and potential to trigger robust innate immune responses. CD BioGlyco offers a specialized mRNA modification service designed to overcome these physiological barriers through the strategic incorporation of modified nucleosides and advanced capping architectures. By chemically tailoring the mRNA transcript, we enable higher protein expression levels, extended intracellular half-lives, and significantly reduced immunogenicity. Our platform utilizes state-of-the-art chemical biology to ensure that every molecule is optimized for its specific therapeutic or research application, whether it be a prophylactic vaccine, a protein replacement therapy, or a complex gene-editing component. Leveraging our expertise in nucleotide chemistry, CD BioGlyco empowers researchers to transition from high-risk discovery to high-performance clinical candidates with precision-engineered RNA.
To deliver world-class modified mRNA, we employ a suite of advanced chemical and enzymatic technologies:
We utilize a comprehensive library of modified triphosphates, including N1-methylpseudouridine, 5-methoxyuridine (5moU), and 5-methylcytidine (m5C), to replace natural nucleotides during in vitro transcription.
Our platform prioritizes Cap-1 structures over Cap-0, utilizing high-efficiency vaccinia capping enzymes or co-transcriptional trinucleotide analogues to mimic natural eukaryotic mRNA and evade detection by MDA5 sensors.
We offer customized poly(A) tailing services, including the incorporation of modified adenosine analogs or segmented tail designs that resist deadenylase activity.
To ensure the fidelity of modifications, we employ LC-MS/MS to quantify the exact percentage of nucleoside substitution and verify the presence of critical chemical signatures.
The mRNA modification service encompasses a wide array of transcript types and chemical options. We support the production of modified linear mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA). Our chemical catalog includes over 50 different modified nucleoside triphosphates, allowing for deep customization of the RNA backbone. We offer service scales ranging from microgram quantities for initial in vitro screening to multi-gram batches for large-scale in vivo studies. Additionally, our scope extends to "Stealth mRNA" packages, which combine complete N1mΨ substitution with proprietary UTR designs to achieve the lowest possible inflammatory profile currently available in the industry.
Our scientific team collaborates with clients to design a tailored mRNA modification strategy, selecting the optimal combination and positioning of modified nucleotides. This selection is based on the target cell type, the desired duration of expression, and the intended application. We evaluate modifications such as pseudouridine or N1-methylpseudouridine to reduce immunogenicity, alongside 5-methylcytosine to fine-tune stability and translational efficiency.
We prepare high-quality DNA templates specifically engineered for modified mRNA production. This includes the chemical synthesis and sequence-optimization of plasmid DNA containing client-specified 5' and 3' untranslated regions (UTRs) that are tailored to work synergistically with the chosen modification profile. The template is then meticulously linearized using high-fidelity restriction enzymes to create a precise run-off transcription start site.
The modified mRNA is synthesized in a precisely optimized, cell-free reaction system. In this step, specific natural ribonucleoside triphosphates (NTPs) are systematically replaced with their modified analogs at defined molar ratios. The reaction conditions, including enzyme concentration, incubation time, and temperature, are carefully controlled to maximize yield, ensure complete incorporation of the modified nucleotides, and maintain the integrity of the full-length transcript.
The newly synthesized mRNA undergoes enzymatic processing to enhance its stability and translational competency. This includes the addition of a Cap-1 structure using a vaccinia virus capping system, and the enzymatic addition of a defined-length poly(A) tail if it is not template-encoded. Following capping and tailing, a DNase treatment step is performed to thoroughly degrade the DNA template, ensuring the final product is free of residual plasmid material.
The crude IVT product is purified through a stringent, multi-step process to remove process-related impurities. We employ tangential flow filtration (TFF) for buffer exchange and initial purification, followed by chromatographic methods such as reverse-phase HPLC or specialized affinity purification. This critical sequence effectively removes detrimental byproducts like double-stranded RNA (dsRNA) and residual NTPs, which are key drivers of unwanted innate immune activation.
The final purified mRNA undergoes a comprehensive suite of analytical tests to confirm it meets stringent release specifications. This includes assessments of integrity via capillary electrophoresis, purity via HPLC, concentration via spectrophotometry, and the precise quantification of the capping efficiency and modification incorporation rate using advanced analytical techniques such as LC-MS, ensuring the product meets all predefined performance and quality standards.
Journal: Accounts of Chemical Research
DOI: 10.1021/acs.accounts.3c00442
IF: 17.7
Published: 2023
Results: This article delves into strategic chemical modifications of the 5'-cap and 3' poly(A) tail of mRNA to overcome inherent stability and immunogenicity challenges, thereby enhancing its efficacy as a therapeutic platform. mRNA serves as a transient blueprint for protein production but requires optimization of its terminal structures to ensure prolonged half-life, efficient translation, and minimized immune activation in clinical applications. Drawing on over two decades of research, the authors detail the design and synthesis of novel cap analogs, such as phosphorothioate derivatives, which strengthen interaction with translation initiation factors like eIF4E and confer resistance to decapping enzymes, significantly boosting protein expression. These modifications have been pivotal in the development of mRNA-based vaccines, including those for COVID-19, and are being explored in cancer immunotherapies. The review also covers innovative methods for end-labeling mRNA to facilitate tracking and purification, underscoring the potential of these engineering approaches to expand the therapeutic landscape for genetic diseases, regenerative medicine, and beyond.
Prophylactic Viral Vaccines
Utilize N1-methylpseudouridine to create vaccines that induce robust antibody titers without the severe systemic inflammation often associated with unmodified RNA, leading to a better safety profile and higher compliance.
Cancer Immunotherapy
Design modified mRNAs encoding tumor antigens or checkpoint inhibitors that can survive the harsh tumor microenvironment and provide sustained protein expression to activate a targeted anti-tumor T-cell response.
Gene Editing (Cas9/Base Editors)
Optimize the expression of Cas9 or other nucleases. By modifying the mRNA, we ensure a high "burst" of enzyme production for efficient editing while minimizing the duration of exposure to reduce off-target risks.
Cell Reprogramming (iPSCs)
Modified mRNA is the gold standard for creating induced pluripotent stem cells. The reduced immunogenicity allows for the daily transfection of transcription factors (OSKM) without inducing cell death, ensuring high reprogramming efficiency.
Maximized Translation Efficiency
Our modified mRNA molecules are designed to enhance the recruitment of the eIF4E translation initiation complex. Cap-1 modified transcripts produced by us yield up to 10-fold more protein than standard Cap-0 or unmodified transcripts in primary cell lines.
Enhanced Nuclease Resistance
Chemical modifications at the 2'-OH position or the use of specific base analogs provide a steric barrier against cellular RNases. This results in a more stable transcript that persists longer in the intracellular environment, reducing the required dosing frequency.
Superior dsRNA Removal
tion techniques specifically tuned to remove double-stranded RNA by-products. This ensures that the benefits of nucleoside modification are not offset by residual impurities that trigger the PKR pathway.
High-Purity Modified NTPs
We use only ultra-high-purity modified nucleotides in our synthesis. This prevents the incorporation of manufacturing impurities that could lead to premature transcript termination or unintended toxicity in sensitive primary cells.
CD BioGlyco's ability to provide 100% modification with >95% Cap-1 efficiency allowed us to move our lead candidate into NHP studies six months ahead of schedule.
— By Manager, RNA Discovery
The custom modification screening library provided by CD BioGlyco helped us identify that 5moU was actually superior to pseudouridine for our specific liver-targeting application.
— By Dr. S.L., Principal Investigator
Technical support at CD BioGlyco is exceptional. They helped us troubleshoot a stability issue and optimized our modification strategy for better nuclease resistance in the lung.
— By Director, Vaccine R&D
Quantitative verification of Cap-1 vs Cap-0 ratios to ensure immune evasion
Precise measurement of tail length distribution using capillary electrophoresis.
Sensitive detection of template DNA to meet regulatory purity requirements.
Ensuring the complete removal of the primary driver of RNA-mediated inflammation.
CD BioGlyco is dedicated to providing the chemical precision required to unlock the therapeutic power of mRNA. Our mRNA modification service ensures that your genetic medicines are stable, potent, and safe. From initial design to large-scale production, we are your partner in RNA excellence, contact us!
Reference
